within Pharmacolibrary.Drugs.ATC.G;

model G03FA17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.76,
    Cl             = 0.025,
    adminDuration  = 600,
    adminMass      = 0.003,
    adminCount     = 1,
    Vd             = 0.004200000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0375,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Drospirenone and estrogen is a combination oral contraceptive containing the progestin drospirenone and an estrogen, usually ethinylestradiol or estradiol. It is primarily used for hormonal contraception in women and may also be used in the management of symptoms of menopause or acne. These products are widely approved and clinically used today as combined oral contraceptives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy premenopausal women after repeated daily oral administration of drospirenone (3 mg) and ethinylestradiol (30 mcg) combination.</p><h4>References</h4><ol><li><p>Regidor, PA, et al., &amp; Mayr, M (2023). Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. <i>Women&#x27;s health (London, England)</i> 19 17455057221147388–None. DOI:<a href=&quot;https://doi.org/10.1177/17455057221147388&quot;>10.1177/17455057221147388</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36744531/&quot;>https://pubmed.ncbi.nlm.nih.gov/36744531</a></p></li><li><p>Nelson, AL (2023). Drospirenone and estetrol: evaluation of a newly approved novel oral contraceptive. <i>Expert opinion on pharmacotherapy</i> 24(16) 1757–1764. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2023.2247979&quot;>10.1080/14656566.2023.2247979</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37691580/&quot;>https://pubmed.ncbi.nlm.nih.gov/37691580</a></p></li><li><p>Battipaglia, C, et al., &amp; Grandi, G (2023). Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 871–879. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2023.2279752&quot;>10.1080/17425255.2023.2279752</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37942662/&quot;>https://pubmed.ncbi.nlm.nih.gov/37942662</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03FA17;
